|Day Low/High||162.37 / 164.77|
|52 Wk Low/High||101.36 / 167.43|
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
The question is whether you want to buy before the breakout or after the breakout?
The bullish reversal pattern is appearing not just in single names, but also in whole sectors.
Here are my thoughts on the quarter and trading the stock.
Watching first-time jobless claims and trading volume, plus some thoughts on defense names like Raytheon and Lockheed Martin, and tech names like Lam Research.
Our technical strategy says that Eli Lilly can be bought on strength over $144, as the name looks more attractive along with others in the health care sector.
These pharmaceutical names have what it takes amid the current crisis and for the long run.
LLY is entering into a new partnership with AbCellera Biologics in an attempt to develop an antibody for Covid-19.
The answer to that question depends on several factors, so let's break them down.
It's no secret that the Fed would like to get out of the short-term repo business.
Here's my strategy which has worked particularly well.
It is nice to once again be sitting in for Doug Kass this Friday at the Daily Diary. I will be coming to you from a Starbucks in downtown Miami this morning, as the internet in my building has decided to opt for a three-day weekend. Oh, the perils o...
The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.
The Medical Technology Stock Letter's top pick rose 357% in 2019.
These healthcare stalwarts look attractive for growth and income.
Shares of the pharmaceutical company received a quant upgrade Monday.
The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.
These stocks are priced for total imperfection. That's just what you want.
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.